The 20-Year Voyage Aboard the Journal of Alzheimer's Disease: Docking at 'Type 3 Diabetes', Environmental/Exposure Factors, Pathogenic Mechanisms, and Potential Treatments

Overview

Journal J Alzheimers Dis

Publisher Sage Publications

Specialties Geriatrics
Neurology

Date 2018 Mar 23

PMID 29562538

Citations 35

Authors

Suzanne M de la Monte

Ming Tong

Jack R Wands

Affiliations

Soon will be listed here.

Abstract

The Journal of Alzheimer's Disease (JAD), founded in 1998, played a pivotal role in broadening the field of research on Alzheimer's disease (AD) by publishing a diverse range of clinical, pathological, molecular, biochemical, epidemiological, experimental, and review articles from its birth. This article recounts my own journey as an author who contributed articles to JAD over the 20 years of the journal's existence. In retrospect, it seems remarkable that a considerable body of work that originated from our group marks a trail that began with studies of vascular, stress, and mitochondrial factors in AD pathogenesis, exploded into the concept of 'Type 3 Diabetes', and continued with the characterization of how environmental, exposure, and lifestyle factors promote neurodegeneration and which therapeutic strategies could reverse the neurodegeneration cascade.

Citing Articles

Type 3 diabetes and metabolic reprogramming of brain neurons: causes and therapeutic strategies.

Meng X, Zhang H, Zhao Z, Li S, Zhang X, Guo R Mol Med. 2025; 31(1):61.

PMID: 39966707 PMC: 11834690. DOI: 10.1186/s10020-025-01101-z.

Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer's Disease.

Ahlawat A, Walia V, Garg M Acta Neurol Belg. 2025; .

PMID: 39762668 DOI: 10.1007/s13760-024-02706-7.

The double life of glucose metabolism: brain health, glycemic homeostasis, and your patients with type 2 diabetes.

Schwartz S, Herman M, Tun M, Barone E, Butterfield D BMC Med. 2024; 22(1):582.

PMID: 39696300 PMC: 11657227. DOI: 10.1186/s12916-024-03763-8.

Thyroid Hormone Supplementation Restores Cognitive Deficit, Insulin Signaling, and Neuroinflammation in the Hippocampus of a Sporadic Alzheimer's-like Disease Rat Model.

Sepulveda P, Ferreira A, Sandoval C, Bergoc G, Moreno A, Nunes M Cells. 2024; 13(21.

PMID: 39513900 PMC: 11545223. DOI: 10.3390/cells13211793.

Diabetes and Cognitive Decline: An Innovative Approach to Analyzing the Biophysical and Vibrational Properties of the Hippocampus.

Do Nascimento Amorim M, Dias Rates E, Isabela Vitoria D, Silva Diniz Filho J, Dos Santos C, Santos-Oliveira R ACS Omega. 2024; 9(39):40870-40881.

PMID: 39371966 PMC: 11447714. DOI: 10.1021/acsomega.4c05869.

References

de la Monte S, Wands J . Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis. 2006; 9(2):167-81. DOI: 10.3233/jad-2006-9209. View

Polvani S, Tarocchi M, Tempesti S, Bencini L, Galli A . Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol. 2016; 22(8):2441-59. PMC: 4768191. DOI: 10.3748/wjg.v22.i8.2441. View

Tong M, de la Monte S . Mechanisms of ceramide-mediated neurodegeneration. J Alzheimers Dis. 2009; 16(4):705-14. PMC: 4550322. DOI: 10.3233/JAD-2009-0983. View

Brody A, Mandelkern M, Jarvik M, Lee G, Smith E, Huang J . Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biol Psychiatry. 2004; 55(1):77-84. DOI: 10.1016/s0006-3223(03)00610-3. View

de la Monte S, Tong M, Schiano I, Didsbury J . Improved Brain Insulin/IGF Signaling and Reduced Neuroinflammation with T3D-959 in an Experimental Model of Sporadic Alzheimer's Disease. J Alzheimers Dis. 2016; 55(2):849-864. PMC: 5575806. DOI: 10.3233/JAD-160656. View

Tong M, Neusner A, Longato L, Lawton M, Wands J, de la Monte S . Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis. 2010; 17(4):827-44. PMC: 2952429. View

Durazzo T, Meyerhoff D, Nixon S . A comprehensive assessment of neurocognition in middle-aged chronic cigarette smokers. Drug Alcohol Depend. 2011; 122(1-2):105-11. PMC: 3258460. DOI: 10.1016/j.drugalcdep.2011.09.019. View

Tong M, Andreani T, Krotow A, Gundogan F, de la Monte S . Potential Contributions of the Tobacco Nicotine-Derived Nitrosamine Ketone to White Matter Molecular Pathology in Fetal Alcohol Spectrum Disorder. Int J Neurol Brain Disord. 2017; 3(2). PMC: 5575815. DOI: 10.15436/2377-1348.16.729. View

Tong M, Longato L, de la Monte S . Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration. BMC Endocr Disord. 2010; 10:4. PMC: 3161394. DOI: 10.1186/1472-6823-10-4. View

10.

Tong M, Deochand C, Didsbury J, de la Monte S . T3D-959: A Multi-Faceted Disease Remedial Drug Candidate for the Treatment of Alzheimer's Disease. J Alzheimers Dis. 2016; 51(1):123-38. PMC: 5577391. DOI: 10.3233/JAD-151013. View

11.

Soreghan B, Thomas S, Yang A . Aberrant sphingomyelin/ceramide metabolic-induced neuronal endosomal/lysosomal dysfunction: potential pathological consequences in age-related neurodegeneration. Adv Drug Deliv Rev. 2003; 55(11):1515-24. DOI: 10.1016/j.addr.2003.07.007. View

12.

Etiene D, Kraft J, Ganju N, Gomez-Isla T, Gemelli B, Hyman B . Cerebrovascular Pathology Contributes to the Heterogeneity of Alzheimer's Disease. J Alzheimers Dis. 2002; 1(2):119-134. DOI: 10.3233/jad-1998-1205. View

13.

Koulmanda M, Qipo A, Chebrolu S, ONeil J, Auchincloss H, Smith R . The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). Am J Transplant. 2003; 3(3):267-72. DOI: 10.1034/j.1600-6143.2003.00040.x. View

14.

Herholz K . Guidance for reading FDG PET scans in dementia patients. Q J Nucl Med Mol Imaging. 2014; 58(4):332-43. View

15.

Gallinat J, Meisenzahl E, Jacobsen L, Kalus P, Bierbrauer J, Kienast T . Smoking and structural brain deficits: a volumetric MR investigation. Eur J Neurosci. 2006; 24(6):1744-50. DOI: 10.1111/j.1460-9568.2006.05050.x. View

16.

Talbot K, Wang H, Kazi H, Han L, Bakshi K, Stucky A . Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012; 122(4):1316-38. PMC: 3314463. DOI: 10.1172/JCI59903. View

17.

Summers S . Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res. 2006; 45(1):42-72. DOI: 10.1016/j.plipres.2005.11.002. View

18.

de la Monte S, Ganju N, Banerjee K, Brown N, Luong T, Wands J . Partial rescue of ethanol-induced neuronal apoptosis by growth factor activation of phosphoinositol-3-kinase. Alcohol Clin Exp Res. 2000; 24(5):716-26. View

19.

de la Monte S, Tong M . Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2009; 17(4):817-25. PMC: 4550318. DOI: 10.3233/JAD-2009-1098. View

20.

Tong M, Dominguez C, Didsbury J, de la Monte S . Targeting Alzheimer's Disease Neuro-Metabolic Dysfunction with a Small Molecule Nuclear Receptor Agonist (T3D-959) Reverses Disease Pathologies. J Alzheimers Dis Parkinsonism. 2016; 6(3). PMC: 4979550. DOI: 10.4172/2161-0460.1000238. View